Trending NewsTrending NewsNASDAQ:GENB Generate Biomedicines (GENB) Stock Price, News & Analysis $10.38 +0.54 (+5.49%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$10.72 +0.33 (+3.23%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Generate Biomedicines Stock (NASDAQ:GENB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Generate Biomedicines alerts:Sign Up Key Stats Today's Range$9.68▼$10.5450-Day Range$9.84▼$17.4652-Week Range$9.68▼$22.67Volume1.05 million shsAverage Volume975,363 shsMarket Capitalization$1.34 billionP/E RatioN/ADividend YieldN/APrice Target$26.20Consensus RatingModerate Buy Company Overview Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma. Generate Biomedicines is led by Chief Executive Officer Mike Nally. The company’s research and development activities are based in the United States, while its medicines are intended for patients in markets where they may ultimately receive regulatory approval.AI Generated. May Contain Errors. Read More Generate Biomedicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreGENB MarketRank™: 2.100684931505 of 5 starsGenerate Biomedicines scored higher than 42% of companies evaluated by MarketBeat, and ranked 1225th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingGenerate Biomedicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGenerate Biomedicines has a consensus price target of $26.20, representing about 152.4% upside from its current price of $10.38.Amount of Analyst CoverageGenerate Biomedicines has only been the subject of 3 research reports in the past 90 days.Read more about Generate Biomedicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Generate Biomedicines are expected to grow in the coming year, from ($2.46) to ($2.38) per share.Price to Book Value per Share RatioGenerate Biomedicines has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.08% of the float of Generate Biomedicines has been sold short.Short Interest Ratio / Days to CoverGenerate Biomedicines has a short interest ratio ("days to cover") of 8.87.Change versus previous monthShort interest in Generate Biomedicines has recently increased by 1.73%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenerate Biomedicines does not currently pay a dividend.Dividend GrowthGenerate Biomedicines does not have a long track record of dividend growth. News and Social Media0.9 / 5News Sentiment-0.52 News SentimentGenerate Biomedicines has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Generate Biomedicines this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for GENB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Generate Biomedicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Generate Biomedicines insiders have not sold or bought any company stock.Percentage Held by InstitutionsGenerate Biomedicines has minimal institutional ownership at this time.Read more about Generate Biomedicines' insider trading history. Receive GENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Generate Biomedicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GENB Stock News HeadlinesHC Wainwright Issues Pessimistic Estimate for GENB Earnings4 hours ago | americanbankingnews.comGenerate Biomedicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 19 at 1:00 AM | Weiss Ratings (Ad)Generate Biomedicines Reports Q3 Results; Cash Runway Extends Into First Half Of 2028; Stock DownNovember 12, 2026 | rttnews.comGenerate Biomedicines GENB Q3 2026: Revenue Misses by 46% as Partner Deals Wind DownNovember 12, 2026 | 247wallst.comGenerate Biomedicines: Q3 earnings snapshotNovember 12, 2026 | msn.comEarnings Flash (GENB) Generate Biomedicines, Inc. Reports Q3 Collaboration Revenue $4.2MNovember 12, 2026 | marketscreener.comMGenerate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12, 2026 | globenewswire.comSee More Headlines GENB Stock Analysis - Frequently Asked Questions How have GENB shares performed this year? Generate Biomedicines' stock was trading at $12.21 on March 10, 2026. Since then, GENB shares have decreased by 15.0% and is now trading at $10.38. How were Generate Biomedicines' earnings last quarter? Generate Biomedicines Inc (NASDAQ:GENB) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.18. The firm had revenue of $4.22 million for the quarter. Generate Biomedicines had a negative net margin of 1,289.97% and a negative trailing twelve-month return on equity of 151.21%. When did Generate Biomedicines IPO? Generate Biomedicines (GENB) raised $400 million in an IPO on Friday, February 27th 2026. The company issued 25,000,000 shares at a price of $15.00-$17.00 per share. Who are Generate Biomedicines' major shareholders? Generate Biomedicines' top institutional investors include Banque Pictet & Cie SA (1.38%), State Street Corp (0.43%), Alps Advisors Inc. (0.13%) and Goldman Sachs Group Inc. (0.11%). How do I buy shares of Generate Biomedicines? Shares of GENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GENB CIK2100782 Webwww.generatebiomedicines.com Phone(888) 469-0055FaxN/AEmployees312Year Founded2018Price Target and Rating Average Price Target for Generate Biomedicines$26.20 High Price Target$30.00 Low Price Target$21.00 Potential Upside/Downside+152.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$203.15 million Net Margins-1,289.97% Pretax Margin-1,321.10% Return on Equity-151.21% Return on Assets-54.73% Debt Debt-to-Equity Ratio0.02 Current Ratio5.01 Quick Ratio5.01 Sales & Book Value Annual Sales$21.07 million Price / Sales63.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book3.52Miscellaneous Outstanding Shares129,097,000Free FloatN/AMarket Cap$1.34 billion OptionableOptionable BetaN/A Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GENB) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Generate Biomedicines Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Generate Biomedicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.